UBS AM’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$795M Sell
7,684,996
-613,102
-7% -$54.7M 0.14% 117
2026
Q1
$596M Sell
8,298,098
-14,243
-0.2% -$1.1M 0.12% 148
2025
Q4
$660M Buy
8,312,341
+387,467
+5% +$30.5M 0.14% 126
2025
Q3
$597M Sell
7,924,874
-1,452,125
-15% -$99.5M 0.13% 132
2025
Q2
$647M Buy
9,376,999
+1,054,177
+13% +$69.1M 0.13% 147
2025
Q1
$564M Sell
8,322,822
-100,786
-1% -$6.03M 0.14% 144
2024
Q4
$378M Buy
8,423,608
+1,373,663
+19% +$77.1M 0.09% 207
2024
Q3
$443M Buy
7,049,945
+107,977
+2% +$6.3M 0.11% 163
2024
Q2
$410M Buy
6,941,968
+1,306,009
+23% +$81.7M 0.12% 148
2024
Q1
$450M Sell
5,635,959
-660,191
-10% -$50.4M 0.16% 121
2023
Q4
$497M Sell
6,296,150
-25,360
-0.4% -$1.8M 0.2% 99
2023
Q3
$441M Sell
6,321,510
-314,000
-5% -$22.2M 0.2% 98
2023
Q2
$493M Hold
6,635,510
0.24% 85
2023
Q1
$493M Buy
6,635,510
+1,209,579
+22% +$101M 0.24% 85
2022
Q4
$506M Buy
5,425,931
+268,082
+5% +$25.9M 0.27% 81
2022
Q3
$492M Sell
5,157,849
-493,240
-9% -$48.8M 0.28% 72
2022
Q2
$524M Buy
5,651,089
+431,731
+8% +$42.1M 0.27% 72
2022
Q1
$528M Sell
5,219,358
-451,506
-8% -$47.4M 0.23% 86
2021
Q4
$585M Buy
5,670,864
+484,834
+9% +$44.8M 0.22% 96
2021
Q3
$440M Sell
5,186,030
-81,410
-2% -$6.82M 0.18% 119
2021
Q2
$440M Sell
5,267,440
-164,864
-3% -$13.5M 0.19% 115
2021
Q1
$409M Buy
5,432,304
+108,612
+2% +$7.91M 0.18% 115
2020
Q4
$364M Buy
5,323,692
+348,206
+7% +$22.6M 0.17% 114
2020
Q3
$291M Buy
4,975,486
+273,547
+6% +$17M 0.16% 124
2020
Q2
$305M Sell
4,701,939
-75,764
-2% -$4.77M 0.19% 111
2020
Q1
$283M Buy
4,777,703
+373,344
+8% +$24.9M 0.2% 94
2019
Q4
$327M Buy
4,404,359
+130,785
+3% +$9.18M 0.2% 95
2019
Q3
$270M Sell
4,273,574
-66,054
-2% -$3.91M 0.18% 113
2019
Q2
$236M Sell
4,339,628
-1,073,447
-20% -$57.8M 0.17% 119
2019
Q1
$292M Sell
5,413,075
-138,995
-3% -$8.58M 0.22% 89
2018
Q4
$364M Buy
5,552,070
+1,785,953
+47% +$133M 0.31% 62
2018
Q3
$296M Sell
3,766,117
-69,186
-2% -$4.95M 0.22% 92
2018
Q2
$247M Sell
3,835,303
-67,829
-2% -$4.47M 0.19% 106
2018
Q1
$243M Buy
3,903,132
+318,483
+9% +$22.9M 0.19% 109
2017
Q4
$260M Buy
3,584,649
+194,553
+6% +$14.1M 0.22% 98
2017
Q3
$276M Buy
3,390,096
+61,839
+2% +$4.89M 0.25% 85
2017
Q2
$268M Buy
3,328,257
+159,577
+5% +$12.6M 0.26% 82
2017
Q1
$249M Sell
3,168,680
-141,619
-4% -$11.3M 0.25% 85
2016
Q4
$261M Sell
3,310,299
-2,114,773
-39% -$171M 0.29% 72
2016
Q3
$483M Buy
5,425,072
+569,065
+12% +$53.7M 0.52% 37
2016
Q2
$465M Buy
4,856,007
+91,148
+2% +$9.08M 0.53% 36
2016
Q1
$494M Buy
4,764,859
+531,568
+13% +$51.7M 0.57% 32
2015
Q4
$414M Sell
4,233,291
-277,847
-6% -$27.2M 0.47% 40
2015
Q3
$435M Sell
4,511,138
-361,511
-7% -$38M 0.48% 40
2015
Q2
$511M Buy
4,872,649
+431,448
+10% +$44.1M 0.49% 39
2015
Q1
$458M Buy
4,441,201
+75,351
+2% +$7.62M 0.44% 47
2014
Q4
$420M Buy
4,365,850
+58,759
+1% +$5.18M 0.4% 51
2014
Q3
$343M Buy
4,307,091
+52,046
+1% +$4.1M 0.34% 68
2014
Q2
$321M Buy
4,255,045
+203,205
+5% +$15.4M 0.32% 68
2014
Q1
$303M Buy
4,051,840
+124,496
+3% +$8.79M 0.32% 68
2013
Q4
$281M Buy
3,927,344
+22,466
+0.6% +$1.44M 0.32% 69
2013
Q3
$222M Sell
3,904,878
-15,624
-0.4% -$931K 0.27% 94
2013
Q2
$224M Buy
+3,920,502
New +$227M 0.29% 86

Other funds holding CVS

UBS AM's CVS Position: Q2 2026 in Review

UBS AM reduced its CVS Health (CVS) stake by 7.4% in Q2 2026, selling an estimated $54.7M and leaving 7,684,996 shares worth $795M. The position accounts for 0.14% of the portfolio, ranked #117.

UBS AM first reported a position in CVS in Q2 2013 and has held it in 53 quarters since. 2,067 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • UBS AM held 7,684,996 shares of CVS Health worth $795M as of Q2 2026.
  • UBS AM sold 613,102 CVS Health shares in Q2 2026, an estimated $54.7M.
  • CVS Health made up 0.14% of UBS AM's portfolio in Q2 2026, its #117 holding.
  • UBS AM first reported a position in CVS Health in Q2 2013 and has held it in 53 quarters since.
  • 2,067 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.